Found: 42
Select item for more details and to access through your institution.
Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01096-6
- By:
- Publication type:
- Article
Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial.
- Published in:
- Journal of Hematology & Oncology, 2019, v. 12, n. 1, p. 1, doi. 10.1186/s13045-018-0691-4
- By:
- Publication type:
- Article
Prognostic gene expression analysis in a retrospective, multinational cohort of 155 multiple myeloma patients treated outside clinical trials.
- Published in:
- International Journal of Laboratory Hematology, 2022, v. 44, n. 1, p. 127, doi. 10.1111/ijlh.13691
- By:
- Publication type:
- Article
Normalization of the Immunological Microenvironment and Sustained Minimal Residual Disease Negativity: Do We Need Both for Long-Term Control of Multiple Myeloma?
- Published in:
- International Journal of Molecular Sciences, 2022, v. 23, n. 24, p. 15879, doi. 10.3390/ijms232415879
- By:
- Publication type:
- Article
Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study
- Published in:
- Stem Cell Research & Therapy, 2015, v. 6, n. 1, p. 1, doi. 10.1186/s13287-015-0033-1
- By:
- Publication type:
- Article
Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell’Adulto Multiple Myeloma Working Party study
- Published in:
- Stem Cell Research & Therapy, 2015, v. 6, n. 1, p. 64, doi. 10.1186/s13287-015-0033-1
- By:
- Publication type:
- Article
Patient‐reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study.
- Published in:
- British Journal of Haematology, 2022, v. 196, n. 3, p. 639, doi. 10.1111/bjh.17887
- By:
- Publication type:
- Article
Gentle yet effective combination therapy with novel agents in elderly multiple myeloma patients.
- Published in:
- British Journal of Haematology, 2018, v. 182, n. 2, p. 165, doi. 10.1111/bjh.15260
- By:
- Publication type:
- Article
MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients.
- Published in:
- British Journal of Haematology, 2014, v. 164, n. 6, p. 841, doi. 10.1111/bjh.12719
- By:
- Publication type:
- Article
Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation.
- Published in:
- 2020
- By:
- Publication type:
- Letter
New Strategies for the Treatment of Older Myeloma Patients.
- Published in:
- Cancers, 2023, v. 15, n. 10, p. 2693, doi. 10.3390/cancers15102693
- By:
- Publication type:
- Article
Diagnostic and Therapeutic Challenges in the Management of Intermediate and Frail Elderly Multiple Myeloma Patients.
- Published in:
- Cancers, 2020, v. 12, n. 11, p. 3106, doi. 10.3390/cancers12113106
- By:
- Publication type:
- Article
Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the OCEAN study.
- Published in:
- European Journal of Haematology, 2024, v. 112, n. 3, p. 402, doi. 10.1111/ejh.14127
- By:
- Publication type:
- Article
Melphalan, Prednisone, and Lenalidomide for Newly Diagnosed Myeloma: Kinetics of Neutropenia and Thrombocytopenia and Time-to-Event Results.
- Published in:
- Clinical Lymphoma & Myeloma, 2009, v. 9, n. 2, p. 145
- By:
- Publication type:
- Article
Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma.
- Published in:
- European Journal of Haematology, 2017, v. 98, n. 3, p. 289, doi. 10.1111/ejh.12834
- By:
- Publication type:
- Article
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 3, p. 165, doi. 10.1016/j.clml.2023.10.009
- By:
- Publication type:
- Article
P-065: CyTOF and single cell RNA sequencing reveal altered T cell phenotypes in Multiple Myeloma patients: implications for immunotherapy.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S74, doi. 10.1016/S2152-2650(21)02199-6
- By:
- Publication type:
- Article
MM-186: HORIZON (OP-106): Melflufen Plus Dexamethasone in 55 Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD): Subgroup Analysis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S427, doi. 10.1016/S2152-2650(21)01953-4
- By:
- Publication type:
- Article
MM-171: Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed or Refractory to Prior Alkylators: A Pooled Analysis of the O-12-M1 and HORIZON Studies.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S426, doi. 10.1016/S2152-2650(21)01952-2
- By:
- Publication type:
- Article
Poster: MM-186: HORIZON (OP-106): Melflufen Plus Dexamethasone in 55 Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD): Subgroup Analysis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S250, doi. 10.1016/S2152-2650(21)01573-1
- By:
- Publication type:
- Article
Poster: MM-171: Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed or Refractory to Prior Alkylators: A Pooled Analysis of the O-12-M1 and HORIZON Studies.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S251, doi. 10.1016/S2152-2650(21)01575-5
- By:
- Publication type:
- Article
Activity of Melflufen in RR MM Patients with Extramedullary Disease in the Phase 2 HORIZON Study (OP-106): Promising Results in a High-Risk Population.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e352, doi. 10.1016/j.clml.2019.09.582
- By:
- Publication type:
- Article
Maintenance Therapy vs Re-treatment at Biochemical Relapse vs Observation in Relapsed/Refractory Multiple Myeloma Patients: Results of a Phase II, Randomized Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e271, doi. 10.1016/j.clml.2019.09.447
- By:
- Publication type:
- Article
Validation of SKY92 high and low risk prognostication in a retrospective, multinational cohort of 155 non-trial multiple myeloma patients.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e60, doi. 10.1016/j.clml.2019.09.094
- By:
- Publication type:
- Article
Clinical and Biological Early Relapse Predictors in Multiple Myeloma: An Analysis from the MMRF CoMMpass Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e13, doi. 10.1016/j.clml.2019.09.019
- By:
- Publication type:
- Article
HORIZON (OP-106) Study of Melflufen in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Daratumumab and/or Pomalidomide: Updated Efficacy and Safety.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S329, doi. 10.1016/j.clml.2019.07.318
- By:
- Publication type:
- Article
Heavy+Light Chain and Free Light Chain Assays at Baseline and During Follow-up in EMN02/HO95 Multiple Myeloma Clinical Trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e47, doi. 10.1016/j.clml.2017.03.084
- By:
- Publication type:
- Article
Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma Patients: A Multicenter, Open Label Phase 1/2 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e59, doi. 10.1016/j.clml.2017.03.108
- By:
- Publication type:
- Article
The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-022-00779-2
- By:
- Publication type:
- Article
Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 2, p. 1, doi. 10.1038/s41408-021-00432-4
- By:
- Publication type:
- Article
High rate of profound clonal and renal responses with daratumumab treatment in heavily pre‐treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 8, p. 900, doi. 10.1002/ajh.25828
- By:
- Publication type:
- Article
Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 3, p. 244, doi. 10.1002/ajh.24621
- By:
- Publication type:
- Article
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study.
- Published in:
- American Journal of Hematology, 2014, v. 89, n. 4, p. 355, doi. 10.1002/ajh.23641
- By:
- Publication type:
- Article
Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Bortezomib, melphalan, and prednisone in elderly patients with relapsed/refractory multiple myeloma: A multicenter, open label phase 1/2 study.
- Published in:
- 2013
- By:
- Publication type:
- Journal Article
Bortezomib, melphalan, and prednisone in elderly patients with relapsed/refractory multiple myeloma.
- Published in:
- Cancer (0008543X), 2013, v. 119, n. 5, p. 971, doi. 10.1002/cncr.27820
- By:
- Publication type:
- Article
The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens.
- Published in:
- Cancer (0008543X), 2011, v. 117, n. 9, p. 1884, doi. 10.1002/cncr.25743
- By:
- Publication type:
- Article
Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma.
- Published in:
- Experimental Hematology & Oncology, 2023, v. 12, n. 1, p. 1, doi. 10.1186/s40164-023-00434-x
- By:
- Publication type:
- Article
Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma.
- Published in:
- Frontiers in Oncology, 2020, p. 1, doi. 10.3389/fonc.2020.00001
- By:
- Publication type:
- Article
Nuances in the Management of Older People With Multiple Myeloma.
- Published in:
- Current Hematologic Malignancy Reports, 2016, v. 11, n. 3, p. 241, doi. 10.1007/s11899-016-0323-4
- By:
- Publication type:
- Article
Treatment of newly diagnosed multiple myeloma.
- Published in:
- Current Hematologic Malignancy Reports, 2008, v. 3, n. 2, p. 107, doi. 10.1007/s11899-008-0016-8
- By:
- Publication type:
- Article